Cargando…

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

New evidence suggests that the clinical success of chemotherapy is not merely due to tumor cell toxicity but also arises from the restoration of immunosurveillance, which has been immensely neglected in previous preclinical and clinical researches. There is an urgent need for novel insights into mol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lin, Zhou, Chao, Zhang, Songou, Chen, Xiaozhen, Liu, Jian, Xu, Fangming, Liang, Wenqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393416/ https://www.ncbi.nlm.nih.gov/pubmed/36003765 http://dx.doi.org/10.3389/fonc.2022.939249

Ejemplares similares

Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity
por: Huang, Xing, et al.
Publicado: (2020)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
por: Jiang, Shuai, et al.
Publicado: (2022)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
por: Chan, Anissa S. H., et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients
por: Zhao, Yue, et al.
Publicado: (2022)

Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Liao, Juan-Yan, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers
por: Wang, Yingnan, et al.
Publicado: (2023)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
por: Liu, Xiaolin, et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
por: Fan, Yong, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Hydrogels for localized chemotherapy of liver cancer: a possible strategy for improved and safe liver cancer treatment
por: Ma, Jianyong, et al.
Publicado: (2022)

Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: Ma, Yue, et al.
Publicado: (2022)

Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Li, Yunhai, et al.
Publicado: (2021)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy
por: Guo, Wenwen, et al.
Publicado: (2021)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer
por: Alshaebi, Fadhl, et al.
Publicado: (2023)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor
por: Pradhan, Anjan K., et al.
Publicado: (2022)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma
por: Bao, Yingying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2unhldj8efuu0dlev2u9ii05ck